Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

THE CONTRIBUTION OF FETAL METABOLISM TO THE DISPOSITION OF MORPHINE

Marianne Garland, Kirsten M. Abildskov, Tung-wah Kiu, Salha S. Daniel and Raymond I. Stark
Drug Metabolism and Disposition January 2005, 33 (1) 68-76; DOI: https://doi.org/10.1124/dmd.104.001388
Marianne Garland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsten M. Abildskov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tung-wah Kiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salha S. Daniel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond I. Stark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The contribution of fetal metabolism to drug disposition in pregnancy is poorly understood. With maternal administration of morphine, like many drugs, steady-state concentrations in fetal plasma are less than in maternal plasma. The contribution of fetal metabolism to this difference is unknown. Morphine was used as a model drug to test the hypothesis that fetal metabolism contributes significantly to drug clearance by the fetus. Infusions of morphine, morphine-3-β-glucuronide (M3G), and morphine-6-β-glucuronide (M6G) were administered to the fetal baboon. Plasma concentrations of drug and metabolite obtained near steady state were measured by high-performance liquid chromatography. During morphine infusion, morphine, M3G, and M6G concentrations rose linearly with dose. M3G concentrations exceeded M6G by 20-fold. Mean ± S.D. clearances of morphine, M3G, and M6G from the fetus were 69 ± 17, 2.3 ± 0.60, and 1.6 ± 0.24 ml · min-1, respectively. Clearances seemed to be dose-independent. The mean ± S.D. fraction of morphine dose metabolized was 32 ± 5.5%. This converts to a fetal metabolic clearance of 22 ± 6.5 ml · min-1. In conclusion, one third of the elimination of morphine from the fetal baboon is attributable to metabolism, one third to passive placental transfer, and one third undefined. Furthermore, there is no evidence for saturation of metabolism. Fetal metabolism is surprisingly high compared with in vitro estimates of metabolism and morphine clearance in human infants. For morphine, fetal drug metabolism accounts for half the difference between fetal and maternal plasma concentrations.

Footnotes

  • This research was supported by the National Institute of Drug Abuse and the Aaron Diamond Foundation. Dr. Garland was a recipient of an Aaron Diamond Postdoctoral Research Fellow.

  • This research was initially presented at the Pediatric Academic Societies' Annual Meeting (2000 May 12-16, Boston, MA; 2001 Apr 28-May 1, Baltimore, MD): Garland M, Abildskov K, Daniel SS, Myers MM, Szeto HH, and Stark RI (2000) Saturation kinetics of morphine glucuronidation in the fetal baboon. Pediatr Res (Part 2; Suppl S): ; and Garland M, Abildskov K, Daniel SS, and Stark RI (2001) Quantification of morphine metabolism by the fetal baboon. Pediatr Res (Part 2; Suppl S): .

  • doi:10.1124/dmd.104.001388.

  • ABBREVIATIONS: UGT, UDP-glucuronosyltransferase; M3G, morphine-3-β-glucuronide; M6G, morphine-6-β-glucuronide; GA, gestational age; HPLC, high-performance liquid chromatography.

    • Received July 8, 2004.
    • Accepted October 14, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 33 (1)
Drug Metabolism and Disposition
Vol. 33, Issue 1
1 Jan 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
THE CONTRIBUTION OF FETAL METABOLISM TO THE DISPOSITION OF MORPHINE
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

THE CONTRIBUTION OF FETAL METABOLISM TO THE DISPOSITION OF MORPHINE

Marianne Garland, Kirsten M. Abildskov, Tung-wah Kiu, Salha S. Daniel and Raymond I. Stark
Drug Metabolism and Disposition January 1, 2005, 33 (1) 68-76; DOI: https://doi.org/10.1124/dmd.104.001388

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

THE CONTRIBUTION OF FETAL METABOLISM TO THE DISPOSITION OF MORPHINE

Marianne Garland, Kirsten M. Abildskov, Tung-wah Kiu, Salha S. Daniel and Raymond I. Stark
Drug Metabolism and Disposition January 1, 2005, 33 (1) 68-76; DOI: https://doi.org/10.1124/dmd.104.001388
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
  • Biotransformation of Trastuzumab and Pertuzumab
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics